EnBiotix: Enhancing antibiotics

EnBiotix using two mechanisms to increase sensitivity to antibiotics

EnBiotix Inc. is discovering compounds that make infections more susceptible to existing antibiotics either by increasing the bacterias' production of reactive oxygen species, or by activating their metabolic pathways. The company is aiming for a discovery alliance followed by an A round that will help fund development of its candidates.

EnBiotix's discovery programs are based on the work of Boston University's James Collins, whose lab has used systems biology approaches to study bacterial responses to antibiotics. Collins is a professor of biomedical engineering

Read the full 820 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE